Content of Premarket Submission for Device Software Functions
FDA issued a draft guidance that identifies the software information generally necessary for evaluating the safety and effectiveness of a device in a premarket submission.
This document is intended to cover:
▪️ firmware and other means for software-based control of medical devices;
▪️ stand-alone software applications;
▪️ software intended to be operated on general-purpose computing platforms;
▪️ dedicated hardware/software medical devices; and
▪️ accessories to medical devices when those accessories contain or are composed of software.
This guidance applies to all types of premarket submissions that include one or more device software function(s).
Comments can be submitted till February 2, 2022.
Consult the FDA guidance.
Contact Meditrial for immediate assistance in Europe and in the US.
We will help you to optimize your global product development program!
Table of Contents
A Practical RBQM Framework for Medical Device Trials
Risk-based quality management for medical device trials, with practical actions for risk assessment, monitoring, data review, and trial oversight
EU Breakthrough Medical Devices Under MDCG 2025-9 (BtX)
EU breakthrough medical devices gain a clearer regulatory pathway under MDCG 2025-9, with early advice and lifecycle evidence planning
What Swissmedic Fast-Track Means for Clinical Trial Sponsors
Swissmedic swissethics Fast-Track Pilot Project accelerates eligible trial reviews and makes coordinated regulatory preparation increasingly important.
FDA Breakthrough Device Acceleration
How innovative MedTech companies can accelerate FDA approval, secure Medicare coverage, and reach patients faster—starting with Breakthrough Device Designation.
The contribution of patient associations in clinical trials
Historically, patient organizations have had the primary purpose of supporting the communities they represented. Today, this remains a crucial function, but modes have changed, as has the role that associations and patients themselves take on [...]
Il contributo delle associazioni pazienti negli studi clinici
In collaborazione con Aboutpharma Storicamente, le organizzazioni dei pazienti hanno avuto lo scopo primario di supportare le comunità che rappresentavano. Oggi questa rimane una funzione cruciale ma le modalità sono cambiate, come [...]
This article provides general information and does not constitute regulatory or legal advice. Requirements should be confirmed for the specific study, applicable regulatory framework, and markets concerned.
